The EGFR Exon 19 Mutant L747-A750&gt;P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma—Letter

Alessandro Di Federico, Daria Maria Filippini, Filippo Gustavo Dall’Olio, Nicole Conci, Roberta Minari, Marcello Tiseo, Andrea Ardizzoni

2020Clinical Cancer Research35 citationsDOI

Abstract

We read with interest the recently published paper by Truini and colleagues (1) describing the peculiar in vitro activity of afatinib on non–small cell lung cancer cell lines harboring the EGFR L747-A750&gt;P mutation.\nWe reviewed our patient database and found 6 cases out of 265 with this specific EGFR mutation (2.2%), similar to the prevalence reported in the paper by Truini and colleagues. Here we report two of those cases, one treated in first-line with afatinib and the other with erlotinib followed by osimertinib at progression.

Topics & Concepts

AfatinibErlotinibOsimertinibMedicineCancer researchErlotinib HydrochlorideTyrosine-kinase inhibitorMutationTyrosine kinaseLung cancerAdenocarcinomaOncologyInternal medicineEpidermal growth factor receptorCancerBiologyGeneGeneticsReceptorLung Cancer Treatments and MutationsQuinazolinone synthesis and applicationsCancer Mechanisms and Therapy

The EGFR Exon 19 Mutant L747-A750&amp;gt;P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma—Letter

Abstract

Topics & Concepts

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma—Letter